Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA

Abstract Background Carcinoembryonic antigen (CEA) levels are used in conjunction with imaging to monitor response to systemic therapy in metastatic colorectal cancer (mCRC). We sought to identify a threshold for CEA change from baseline to predict progressive disease (PD) in mCRC patients receiving...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2020-11, Vol.112 (11), p.1127-1136
Hauptverfasser:	Gulhati, Pat, Yin, Jun, Pederson, Levi, Schmoll, Hans-Joachim, Hoff, Paulo, Douillard, Jean-Yves, Hecht, J Randolph, Tournigand, Christophe, Tebbut, Niall, Chibaudel, Benoist, Gramont, Aimery De, Shi, Qian, Overman, Michael James
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies Antigens Cancer Carcinoembryonic antigen Carcinoembryonic Antigen - blood Chemotherapy Clinical trials Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - blood Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Colorectal Neoplasms - therapy Computed tomography Disease Progression Epidermal growth factor receptors Female Humans Male Metastases Metastasis Middle Aged Neoplasm Metastasis Neoplasm Staging Patients Predictions Predictive Value of Tests Randomized Controlled Trials as Topic ROC Curve Sensitivity analysis Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!